Chicago ENT / Chicago Sleep Center accelerates patient outcomes, reduces overhead with EnsoHST

In 2024, Chicago ENT/Chicago Sleep Center (CENT/CSC) explored EnsoHST, an FDA-cleared, multi-night AI-powered home sleep testing solution that leverages data from pulse oximeters, to streamline the home testing process, reduce device costs, and expedite patient outcomes.

Since adding EnsoHST in August 2024, CENT/CSC has transitioned more than 75% of their home testing volume from legacy HSTs with a nasal cannula to EnsoHST, all in just 3 months. With the power of EnsoHST, CENT/CSC has been able to pivot to more affordable devices, reducing per device costs from $2,000 to $150.

Dive into the full case study to explore CENT/CSC’s rapid and efficient adoption and the significant benefits of adding affordable devices and cutting edge AI.